JP2018526981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526981A5 JP2018526981A5 JP2018501159A JP2018501159A JP2018526981A5 JP 2018526981 A5 JP2018526981 A5 JP 2018526981A5 JP 2018501159 A JP2018501159 A JP 2018501159A JP 2018501159 A JP2018501159 A JP 2018501159A JP 2018526981 A5 JP2018526981 A5 JP 2018526981A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- cdr2
- cdr1
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021168124A JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
| JP2024216521A JP2025038049A (ja) | 2015-07-15 | 2024-12-11 | ヒト化またはキメラｃｄ３抗体 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500414 | 2015-07-15 | ||
| DKPA201500414 | 2015-07-15 | ||
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500416 | 2015-07-16 | ||
| DKPA201500416 | 2015-07-16 | ||
| EPPCT/EP2016/050296 | 2016-01-08 | ||
| PCT/EP2016/050296 WO2016110576A1 (en) | 2015-01-08 | 2016-01-08 | Bispecific antibodies against cd3 and cd20 |
| PCT/EP2016/066845 WO2017009442A1 (en) | 2015-07-15 | 2016-07-14 | Humanized or chimeric cd3 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021168124A Division JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018526981A JP2018526981A (ja) | 2018-09-20 |
| JP2018526981A5 true JP2018526981A5 (https=) | 2019-08-29 |
Family
ID=57757079
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501159A Pending JP2018526981A (ja) | 2015-07-15 | 2016-07-14 | ヒト化またはキメラｃｄ３抗体 |
| JP2021168124A Active JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
| JP2024216521A Pending JP2025038049A (ja) | 2015-07-15 | 2024-12-11 | ヒト化またはキメラｃｄ３抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021168124A Active JP7604351B2 (ja) | 2015-07-15 | 2021-10-13 | ヒト化またはキメラｃｄ３抗体 |
| JP2024216521A Pending JP2025038049A (ja) | 2015-07-15 | 2024-12-11 | ヒト化またはキメラｃｄ３抗体 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11359015B2 (https=) |
| EP (1) | EP3322727B1 (https=) |
| JP (3) | JP2018526981A (https=) |
| KR (2) | KR102786353B1 (https=) |
| CN (3) | CN120842408A (https=) |
| AU (2) | AU2016293073B2 (https=) |
| BR (1) | BR112018000696A2 (https=) |
| CA (1) | CA2992380A1 (https=) |
| DK (1) | DK3322727T3 (https=) |
| EA (1) | EA201890305A1 (https=) |
| ES (1) | ES3063317T3 (https=) |
| FI (1) | FI3322727T3 (https=) |
| IL (2) | IL256562B2 (https=) |
| MX (2) | MX395317B (https=) |
| NZ (1) | NZ739028A (https=) |
| PT (1) | PT3322727T (https=) |
| SI (1) | SI3322727T1 (https=) |
| UA (1) | UA128057C2 (https=) |
| WO (1) | WO2017009442A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| DK3592769T3 (da) | 2017-03-09 | 2024-08-12 | Genmab As | Antistoffer mod pd-l1 |
| US11668021B2 (en) | 2017-05-09 | 2023-06-06 | Yale University | Basehit, a high-throughput assay to identify proteins involved in host-microbe interaction |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| AR112257A1 (es) | 2017-06-21 | 2019-10-09 | Gilead Sciences Inc | Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos |
| SG11202000198QA (en) | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| SG11202008399QA (en) | 2018-03-12 | 2020-09-29 | Genmab As | Antibodies |
| CN120399075A (zh) * | 2018-03-14 | 2025-08-01 | 诺维莫尼公司 | 抗-CD3ε抗体及其应用方法 |
| MX2021002301A (es) * | 2018-08-28 | 2021-04-28 | Ambrx Inc | Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos. |
| MX2021014973A (es) * | 2019-06-07 | 2022-04-18 | Adimab Llc | Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso. |
| AU2020323925A1 (en) * | 2019-07-29 | 2022-03-17 | Stadius Biopharma, LLC | Antibodies to Candida and uses thereof |
| WO2021048423A1 (en) | 2019-09-12 | 2021-03-18 | Genmab A/S | Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
| MX2022009936A (es) | 2020-03-18 | 2022-09-12 | Genmab As | Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4). |
| MX2022013797A (es) | 2020-05-08 | 2022-11-30 | Genmab As | Anticuerpos biespecificos contra cd3 y cd20. |
| KR20230066040A (ko) | 2020-09-10 | 2023-05-12 | 젠맵 에이/에스 | 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체 |
| US20240034812A1 (en) | 2020-09-10 | 2024-02-01 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| JP2023547329A (ja) * | 2020-10-02 | 2023-11-10 | ジェンマブ エー／エス | Ｒｏｒ２へと結合することができる抗体ならびにｒｏｒ２およびｃｄ３に結合する二重特異性抗体 |
| WO2022234146A1 (en) | 2021-05-07 | 2022-11-10 | Genmab A/S | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3 |
| CN113527493B (zh) * | 2021-07-20 | 2023-10-27 | 广州爱思迈生物医药科技有限公司 | 一种b7-h3抗体及其应用 |
| EP4413039A1 (en) * | 2021-10-08 | 2024-08-14 | Genmab A/S | Antibodies binding to cd30 and cd3 |
| CN115368446B (zh) * | 2022-07-19 | 2025-08-08 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| AR132290A1 (es) | 2023-04-05 | 2025-06-11 | Genmab As | Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| ES2593484T3 (es) | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| DK2786762T3 (da) | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| AU2012245116A1 (en) * | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| KR102060389B1 (ko) | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| EP2892924B1 (en) | 2012-06-14 | 2020-11-25 | Therapix Biosciences Ltd. | Humanized antibodies to cluster of differentiation 3 (cd3) |
| WO2013188693A1 (en) * | 2012-06-15 | 2013-12-19 | Imaginab, Inc. | Antigen binding constructs to cd3 |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| ES2758979T3 (es) | 2012-07-06 | 2020-05-07 | Genmab Bv | Proteína dimérica con mutaciones triples |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| US10544220B2 (en) | 2015-01-08 | 2020-01-28 | Genmab A/S | Bispecific antibodies against CD3 and CD20 |
-
2016
- 2016-07-14 IL IL256562A patent/IL256562B2/en unknown
- 2016-07-14 KR KR1020187004157A patent/KR102786353B1/ko active Active
- 2016-07-14 SI SI201631947T patent/SI3322727T1/sl unknown
- 2016-07-14 UA UAA201801453A patent/UA128057C2/uk unknown
- 2016-07-14 NZ NZ739028A patent/NZ739028A/en unknown
- 2016-07-14 CA CA2992380A patent/CA2992380A1/en active Pending
- 2016-07-14 CN CN202511003204.5A patent/CN120842408A/zh active Pending
- 2016-07-14 BR BR112018000696-3A patent/BR112018000696A2/en active IP Right Grant
- 2016-07-14 AU AU2016293073A patent/AU2016293073B2/en active Active
- 2016-07-14 CN CN202210585379.1A patent/CN114989302B/zh active Active
- 2016-07-14 ES ES16739459T patent/ES3063317T3/es active Active
- 2016-07-14 PT PT167394592T patent/PT3322727T/pt unknown
- 2016-07-14 JP JP2018501159A patent/JP2018526981A/ja active Pending
- 2016-07-14 DK DK16739459.2T patent/DK3322727T3/da active
- 2016-07-14 EA EA201890305A patent/EA201890305A1/ru unknown
- 2016-07-14 KR KR1020257009196A patent/KR20250048113A/ko active Pending
- 2016-07-14 US US15/744,317 patent/US11359015B2/en active Active
- 2016-07-14 WO PCT/EP2016/066845 patent/WO2017009442A1/en not_active Ceased
- 2016-07-14 EP EP16739459.2A patent/EP3322727B1/en active Active
- 2016-07-14 IL IL310467A patent/IL310467A/en unknown
- 2016-07-14 CN CN201680054638.0A patent/CN108368172B/zh active Active
- 2016-07-14 FI FIEP16739459.2T patent/FI3322727T3/fi active
- 2016-07-14 MX MX2018000347A patent/MX395317B/es unknown
-
2018
- 2018-01-09 MX MX2022011002A patent/MX2022011002A/es unknown
-
2021
- 2021-10-13 JP JP2021168124A patent/JP7604351B2/ja active Active
-
2022
- 2022-05-09 US US17/739,923 patent/US20220380464A1/en active Pending
- 2022-05-09 US US17/739,940 patent/US20220389101A1/en active Pending
-
2023
- 2023-03-20 AU AU2023201733A patent/AU2023201733A1/en active Pending
-
2024
- 2024-12-11 JP JP2024216521A patent/JP2025038049A/ja active Pending